Microscreen Split Cup Urine Test (AS/NZS 4308:2023)

The Thermo Fisher MicroScreen SPLIT urine drug testing cup is a six-panel split-specimen cup designed for workplace and forensic screening under AS/NZS 4308:2023. The key-activated split design keeps the sample secure until the collector is ready to start the test, with built-in temperature and adulterant checks to support chain-of-custody. Results are typically available within 5 minutes. Each device is NEOVAULT enabled, with optional digital reporting and secure chain of custody once a NEOVAULT account is activated.

Key features:

• Six-drug panel, key-activated split cup for workplace and forensic screening
• Independently validated against AS/NZS 4308:2023 workplace urine drug testing standard
• Split specimen design with A and B samples to support confirmatory or referee testing if required.
• Two sealed chambers (A and B) created at collection to maintain chain of custody.
• Built-in temperature strip and adulterant panel for specimen integrity checks
• Clear, easy-to-read results window with visual lines in around 5 minutes (do not read after 10 minutes)
• Box of 25 cups, suitable for clinic, onsite or remote workplace programs
• Optional NEOVAULT digital reporting layer for QR-based chain-of-custody and digital records management

Specifications:

• Specimen type: Urine
• Adulterant and integrity checks
• Built-in temperature strip
• Adulterant panel: Creatinine (CRE), Nitrate (NIT), pH, Specific Gravity (SG) and Bleach (BL) to help detect diluted or tampered specimens

Drug classes screened (6-panel):

• Amphetamine (AMP)
• Methamphetamine (MET)
• Benzodiazepines (BZO)
• Cannabis / THC (THC)
• Cocaine (COC)
• Opiates (OPI / MOP)

Screening cut-off levels (Aligned to AS/NZS 4308:2023 compliant screening levels):

• Amphetamine (AMP): 300 ng/mL
• Methamphetamine (MET): 300 ng/mL
• Benzodiazepines (BZO): 200 ng/mL
• Cannabis / THC (THC): 50 ng/mL
• Cocaine (COC): 300 ng/mL
• Opiates (OPI / MOP): 300 ng/mL

Standards and validation:

• Designed and validated for use under AS/NZS 4308:2023 compliant workplace urine drug testing
• Supports split-specimen collection for referee / confirmation testing as required under AS/NZS 4308:2023.

Performance:

• Result time: typically 5 minutes (read between 5-10 minutes per IFU)
• Qualitative onsite screening test (non-negative results to be confirmed by accredited laboratory)

NEOVAULT digital chain-of-custody (optional)

Kits are supplied NEOVAULT enabled for organisations that activate a NEOVAULT account. Each test is captured via a unique QR code or manual selection in the NEOVAULT app, so every result sits under a secure per donor record with time stamped chain of custody, full result history and exportable reports. NEOVAULT can also link DRUID impairment checks and laboratory confirmations under the same record, replacing paper forms and spreadsheets and significantly reducing manual handling, admin time and internal cost per test. The platform is hosted in Australian data centres and designed to align with SOC 2, ISO 27001, GDPR and HIPAA style security and privacy controls, with role based access and full audit trails. Access and setup are managed separately to kit purchases and are included subject to an agreed annual minimum order quantity, with no integration required to get started.